At Apellis, we are committed to developing transformative therapies for people living with a broad range of debilitating diseases by controlling complement, part of the body’s immune system. Our work is rooted centrally at C3, which is the only target in the complement cascade that addresses all three pathways that can drive disease. Targeting C3 has broad platform potential to treat many diseases where patients have few or no treatment options available. Our programs across ophthalmology, nephrology, hematology, and neurology are further exploring what is possible by targeting C3. You can view our community guidelines here: Community guidelines: http://bit.ly/476Q8

Solasta Ventures

Sectoral Asset Management

Cormorant Asset Management

Epidarex Capital

F-Prime Capital

Vivo Capital

Clough Capital Partners

Sofinnova Investments

venBio Partners

Morningside Venture Investments

Morningside Ventures

Apellis Pharmaceuticals

There are over 7,000 rare diseases, and only 5% of them have an approved treatment. We take pride in supporting patients like Ashley, who is living with #PNH, a rare and potentially life-threatening blood disease.

Learn more about our commitment to the rare disease community: https://bit.ly/4baXFv2 #WeAreApellis

At Apellis, our values are not just how we operate. They’re who we are. 

Learn more about what makes our Apellis culture special: https://bit.ly/3S2LVC2 #WeAreApellis

We’re pleased to share a preliminary fourth quarter and full year revenue update. Apellis CEO Cedric Francois will be discussing these updates and our 2024 priorities today at the J.P. Morgan Healthcare Conference at 9:45 a.m. PT. 

Read more: https://bit.ly/3NWft30 #JPM24 $APLS

Mark your calendar – Apellis CEO Cedric Francois will be presenting at #JPM24 on Monday, January 8! Learn more: https://bit.ly/48jYbVL

At Apellis, our science starts with the complement cascade. The complement cascade may be activated by 3 pathways, all converging at C3. C3 controls all downstream effects that can drive disease: cell removal, inflammation & cell death or dysregulation. 

Learn more: https://lnkd.in/gaUxCxFu

Today, we announced an update on the ongoing regulatory review of our geographic atrophy treatment in the European Union. https://bit.ly/3REfRVY

We are proud to share new data that reinforce the long-term efficacy and safety our paroxysmal nocturnal hemoglobinuria (#PNH) treatment. These post hoc data were presented over the weekend at the American Society of Hematology Annual Meeting. #ASH23

https://bit.ly/3Njb4GY

At Apellis, our values are the roadmap for people, guiding every decision, and every action we take. Each year, we celebrate Apellucians who go above and beyond to live by these values in our annual awards ceremony. Join us in celebrating them! #WeAreApellis

Did you know it's #GeographicAtrophy (GA) Awareness week? GA is the dry, advanced form of #AMD. This hits close to home for Henry Winkler whose father-in-law, Ed, experienced AMD. Learn more about GA and our partnership at GAwontwait.com. #WeAreApellis

We’re proud to support the inaugural World #GeographicAtrophy (GA) Day in partnership with BrightFocus Foundation, Macular Society, Fighting Blindness Canada and Prevent Blindness 🌍 

Help us raise awareness and provide support for the 5 million people worldwide living with GA. #WorldGADay #WeAreApellis

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.

COM:APELLIS

Apellis Pharmaceuticals, Inc.

Last Close

27.75

22/11 21:00

Market Cap

4.54B

Beta: -

Volume Today

2.66M

Avg: -

Filings Not Available